These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28431665)

  • 1. GLP-1 receptor agonist confer target organ protection in type 2 diabetes.
    Bonnet F
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S1-2S2. PubMed ID: 28431665
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GLP-1 receptor agonists: current state].
    Larger É; Dehghani L; Saatdjian L; Wucher H
    Rev Prat; 2015 Oct; 65(8):1037-8. PubMed ID: 26749700
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.
    McCarthy M
    BMJ; 2015 Dec; 351():h6702. PubMed ID: 26656272
    [No Abstract]   [Full Text] [Related]  

  • 5. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley RE
    Diabetes Technol Ther; 2016 Nov; 18(11):671-673. PubMed ID: 27860501
    [No Abstract]   [Full Text] [Related]  

  • 6. Research digest: pioneering an oral GLP-1 receptor agonist.
    Atkinson MA; Powers AC
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):897. PubMed ID: 31748168
    [No Abstract]   [Full Text] [Related]  

  • 7. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
    Baron HL
    J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
    Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S
    Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.
    Bacha F
    Lancet Child Adolesc Health; 2019 Sep; 3(9):595-597. PubMed ID: 31345736
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of the once-weekly GLP-1 receptor agonists from the pharmacist's perspective.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):3-6. PubMed ID: 32910491
    [No Abstract]   [Full Text] [Related]  

  • 11. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Leiter LA; Nauck MA
    Exp Clin Endocrinol Diabetes; 2017 Jul; 125(7):419-435. PubMed ID: 28724168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
    Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
    Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Injectable Drug for Type 2 Diabetes.
    Aschenbrenner DS
    Am J Nurs; 2016 Nov; 116(11):22-23. PubMed ID: 27787319
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 19. Lixisenatide for type 2 diabetes.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):19-21. PubMed ID: 28118649
    [No Abstract]   [Full Text] [Related]  

  • 20. The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes.
    Montori VM; Rodriguez-Gutierrez R
    Ann Intern Med; 2016 Jan; 164(2):127-8. PubMed ID: 26641027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.